BR112015012380A2 - vírus influenza recombinante - Google Patents

vírus influenza recombinante

Info

Publication number
BR112015012380A2
BR112015012380A2 BR112015012380A BR112015012380A BR112015012380A2 BR 112015012380 A2 BR112015012380 A2 BR 112015012380A2 BR 112015012380 A BR112015012380 A BR 112015012380A BR 112015012380 A BR112015012380 A BR 112015012380A BR 112015012380 A2 BR112015012380 A2 BR 112015012380A2
Authority
BR
Brazil
Prior art keywords
recombinant influenza
influenza virus
recombinant
influenza
production
Prior art date
Application number
BR112015012380A
Other languages
English (en)
Inventor
Trusheim Heidi
Mason Peter
Ralph Dormitzer Philip
Suphaphiphat Pirada
Original Assignee
Novartis Ag
Synthetic Genomics Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Synthetic Genomics Vaccines Inc filed Critical Novartis Ag
Publication of BR112015012380A2 publication Critical patent/BR112015012380A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Abstract

resumo vírus influenza recombinante novas estirpes dadoras da gripe para a produção de vírus a da gripe recombinante natural são fornecidos.
BR112015012380A 2012-12-03 2013-12-02 vírus influenza recombinante BR112015012380A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732809P 2012-12-03 2012-12-03
PCT/EP2013/075294 WO2014086732A2 (en) 2012-12-03 2013-12-02 Influenza virus reassortment

Publications (1)

Publication Number Publication Date
BR112015012380A2 true BR112015012380A2 (pt) 2017-09-12

Family

ID=49713076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012380A BR112015012380A2 (pt) 2012-12-03 2013-12-02 vírus influenza recombinante

Country Status (11)

Country Link
US (3) US9708585B2 (pt)
EP (1) EP2925356A2 (pt)
JP (1) JP6421128B2 (pt)
KR (1) KR20150110494A (pt)
CN (1) CN105120893B (pt)
AU (2) AU2013354219A1 (pt)
BR (1) BR112015012380A2 (pt)
CA (1) CA2893429A1 (pt)
HK (1) HK1214959A1 (pt)
MX (1) MX2015006927A (pt)
WO (1) WO2014086732A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120893B (zh) * 2012-12-03 2018-11-13 诺华股份有限公司 流感病毒重配
WO2016172588A1 (en) * 2015-04-24 2016-10-27 Andrew Cox Attenuated influenza vaccines and uses thereof
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
GB201602535D0 (en) * 2016-02-12 2016-03-30 Univ Edinburgh Improved flu vaccine yield
WO2019044636A1 (ja) * 2017-08-28 2019-03-07 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルスの段階的作出方法
JP7320601B2 (ja) * 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
KR101954904B1 (ko) 2018-10-15 2019-03-06 남종규 복층의 태양광 설치 구조
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DK1098961T3 (da) 1998-06-12 2008-05-26 Andrej Y Dr Egorov Gensplejsede svækkede vira, der inducerer interferon
ATE376825T1 (de) 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
KR100797547B1 (ko) 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
WO2002074336A2 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
KR20070060049A (ko) 2004-05-20 2007-06-12 아이디 바이오메디칼 코포레이션 인플루엔자 백신의 제조방법
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
JP2008543331A (ja) 2005-06-21 2008-12-04 メッドイミューン バクシーンズ，インコーポレイティド イヌ細胞中でウイルスのネガティブセンスｒｎａを発現する方法および組成物
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
PT2301572E (pt) 2005-11-01 2014-12-22 Novartis Vaccines & Diagnostic Vacinas virais derivadas de células com níveis baixos de adn celular residual
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9254318B2 (en) * 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
CN101528941B (zh) 2006-04-19 2014-03-12 米迪缪尼有限公司 在犬细胞中表达负义病毒rna的方法和组合物
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EP2376628B1 (en) 2008-12-16 2018-05-16 Ology Bioservices, Inc. Production of influenza vaccines
EP2233152A1 (en) * 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
SG10201403557QA (en) * 2009-06-25 2014-10-30 Medimmune Llc Swine influenza hemagglutinin variants
KR20120039047A (ko) 2009-07-31 2012-04-24 노파르티스 아게 역유전학 시스템
JP5876036B2 (ja) * 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
CN105120893B (zh) * 2012-12-03 2018-11-13 诺华股份有限公司 流感病毒重配

Also Published As

Publication number Publication date
JP2016501020A (ja) 2016-01-18
CN105120893B (zh) 2018-11-13
CN105120893A (zh) 2015-12-02
US20200155666A1 (en) 2020-05-21
JP6421128B2 (ja) 2018-11-07
CA2893429A1 (en) 2014-06-12
WO2014086732A2 (en) 2014-06-12
AU2018232956B2 (en) 2020-10-01
US20150315548A1 (en) 2015-11-05
US10500266B2 (en) 2019-12-10
AU2013354219A1 (en) 2015-07-02
US20170326227A1 (en) 2017-11-16
EP2925356A2 (en) 2015-10-07
WO2014086732A8 (en) 2018-12-06
KR20150110494A (ko) 2015-10-02
AU2018232956A1 (en) 2018-10-11
WO2014086732A3 (en) 2014-07-24
MX2015006927A (es) 2016-02-05
US9708585B2 (en) 2017-07-18
HK1214959A1 (zh) 2016-08-12

Similar Documents

Publication Publication Date Title
BR112015021880A2 (pt) rearranjo de vírus influenza b
BR112015012380A2 (pt) vírus influenza recombinante
CO7151521A2 (es) Anticuerpos anti-fcrn
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
CL2015001052A1 (es) Licuefacción de gas natural.
FI11357U1 (fi) Ilmarengas
TWD168095S (zh) 瓶子
DK2931877T3 (da) Fremgangsmåder, som modulerer stamcellers immunregulerende virkning
BR112015008272A2 (pt) cápsula para preparação de bebidas
MX2015016755A (es) Reagrupamiento del virus de influenza.
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
TWD168096S (zh) 瓶子
WO2013087945A3 (en) Influenza virus reassortment
TWD169384S (zh) 包裝盒
MX370649B (es) Proceso para la preparacion de teneligliptina.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
FR2988733B1 (fr) Microorganisme recombinant
CL2011002403S1 (es) Luminaria solar.
BR112014005281A2 (pt) manipulador pneumático balanceado
FI20126010A (fi) Lähdekohteiden muuntaminen kohdekohteiksi
TWD172103S (zh) 瓶子
CO7111295A2 (es) Anticuerpo anti-rob04
BR112015017420A2 (pt) recombinação de vírus influenza
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH) ; SYNTHETIC GENOMICS, INC. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: NOVARTIS AG (CH) ; SYNTHETIC GENOMICS, INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2502 DE 18/12/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH) ; SYNTHETIC GENOMICS, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2647 DE 28/09/2021.